143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial

Gautschi, Oliver; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, D; Pless, M; Froesch, P; Mach, Nicolas; Ochsenbein, A

doi:10.1016/S1556-0864(16)30253-2

Scientific article

English

143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial

ContributorsGautschi, Oliver; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, D; Pless, M; Froesch, P; Mach, Nicolas; Ochsenbein, A

Published inJournal of thoracic oncology, vol. 11, no. 4 Suppl, S120

Publication date2016

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de chirurgie

Research groups

Citation (ISO format)

GAUTSCHI, Oliver et al. 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. In: Journal of thoracic oncology, 2016, vol. 11, n° 4 Suppl, p. S120. doi: 10.1016/S1556-0864(16)30253-2

Article (Published version)

OA OTHER

Identifiers

PID : unige:93755
DOI : 10.1016/S1556-0864(16)30253-2
PMID : 27198283

Journal ISSN1556-0864

524views

182downloads

Creation07/03/2017 15:24:00

First validation07/03/2017 15:24:00

Update08/10/2024 15:17:30

Status update08/10/2024 15:17:30

Last indexation31/10/2024 06:48:34

Archive ouverte UNIGE

143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial

Technical informations